The SA Health Products Regulatory Authority (SAHPRA) has recommended updating the safety warnings for the popular contraceptive injection Depo-Provera to include the potential risk of meningioma. - reported News24 (20 Jan 2025).
“This decision follows two epidemiological studies conducted in France and the United States, which observed an increased risk of meningioma with prolonged use of medroxyprogesterone acetate (MPA), the active ingredient in Depo Provera. Pfizer, the manufacturer of Depo-Provera, maintains that the contraceptive is safe and effective.”